| |
| Issue |
Title |
| |
| No 11 (2023) |
Place of fulvestrant in the treatment of patients with metastatic luminal Her2-negative breast cancer |
Abstract
PDF (Rus)
|
|
M. A. Frolova, M. B. Stenina |
| |
| No 9 (2020) |
Is the extension of adjuvant hormone therapy for breast cancer justified? |
Abstract
PDF (Rus)
|
|
V. F. Semiglazov, V. S. Apollonova |
| |
| No 9 (2020) |
Fulvestrant in the treatment of luminal metastatic breast cancer: the balance of effectiveness and safety |
Abstract
PDF (Rus)
|
|
I. A. Koroleva, M. V. Kopp |
| |
| No 19 (2019) |
Fulvestrant in treatment for metastatic breast cancer |
Abstract
PDF (Rus)
|
|
L. Yu. Vladimirova, I. L. Popova, N. A. Abramova, A. E. Storozhakova, N. M. Tikhanovskaya, K. A. Novoselova, A. A. L’yanova, L. A. Ryadinskaya, M. O. Ezhova, M. A. Teplyakova, L. K. Strakhov |
| |
| No 19 (2019) |
The renaissance of endocrine therapy in hormone sensitive breast cancer |
Abstract
PDF (Rus)
|
|
article Editorial |
| |
| No 10 (2019) |
Efficacy and safety of adjuvant ovarian suppression with Buserelin-depo in premenopausal women with hormone-positive breast cancer |
Abstract
PDF (Rus)
|
|
L. K. Ovchinnikova, A. D. Belko |
| |
| No 19 (2018) |
Adjuvant therapy in premenopausal women with hormone-dependent breast cancer |
Abstract
PDF (Rus)
|
|
V. F. Semiglazov, V. Yu. Lifanova, V. S. Appolonova |
| |
| No 19 (2018) |
Tactics for minimizing risk of increasing estradiol against the background of aromatase inhibitors in combination with gonadotropin releasing hormone agonists in adjuvant therapy for breast cancer in premenopausal patients. Pilot study results |
Abstract
PDF (Rus)
|
|
I. B. Kononenko, A. V. Snegovoi, L. V. Manzyuk, E. I. Kovalenko, V. Yu. Selchuk |
| |
| No 10 (2018) |
Adverse effects of adjuvant endocrine therapy |
Abstract
PDF (Rus)
|
|
E. I. Kovalenko, I. B. Kononenko, A. V. Snegovoi, O. P. Grebennikova, L. V. Manzyuk |
| |
| 1 - 9 of 9 Items |
|
